Heart 2006;92:1191-1193
EDITORIAL
The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention
Correspondence to:
Dr Scott Harding
Department of Cardiology, Wellington Hospital, Private Bag 7902, Wellington, New Zealand; scott.harding{at}ccdhb.org.nz
The routine use of vasodilators in patients with acute coronary syndromes or other groups undergoing percutaneous coronary intervention (PCI) cannot be recommended at present. However, in the event of no-reflow occurring following PCI, intracoronary adenosine or verapamil should be administered
Abbreviations: AMISTAD, Acute Myocardial Infarction STudy of Adenosine; PCI, percutaneous coronary intervention; SVG, saphenous vein graft; TIMI, Thrombolysis in Myocardial Infarction
Keywords: no-reflow; vasodilators; adenosine; verapamil
Relevant Articles
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Heart 2006 92: 1865.
Heart 2006 92: 1691.
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
hrt.2006.088427v1
92/9/1191 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
